Regional One Health and UTHSC to conduct clinical trials of Regeneron's COVID treatment

The Regeneron drug candidate consists of a two-antibody cocktail that binds to SARS-CoV2’s spike protein, which potentially neutralizes the virus’ ability to attach to human cells.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.